6MW3211

· Mabwell (Shanghai) Bioscience Co., Ltd.

Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for 6MW3211, covering 2022-05-09 to 2023-03-15. Get the full timeline:

Most recent: Clinical Trial Update: A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS [Phase 1, Phase 2]